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ABSTRACT
Incidence of hepatocellular carcinoma (HCC) continues to increase in developing countries and rank 5th in 
male and 7th in female. Main cause being reported is chronic hepatitis B in Asian region. Treatment of choice for 
HCC is liver resection, however it is oftenly not possible to be performed as the disease has entered advanced 
stage. Due to the less choice of treatment in HCC, one of the several other alternatives has been considered is 
transarterial chemoembolization (TACE) which is applied in patients who cannot undergo resection or ablation 
therapy, failure of therapy. However limitation of TACE is very high recurrence rate of HCC. Sorafenib is an 
anti-angiogenic medicine approved as first systemic drug in HCC therapy. Several studies stated the benefits 
of combination therapy of TACE and Sorafenib administration to prevent HCC recurrence. Success rate of this 
combination therapy reaches control disease rate of 100% based on  response evaluation criteria in solid tumors 
(RECIST) from European Association for the Study of the Liver (EASL).
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ABSTRAK
Insiden dari karsinoma hepatoseluler (KHS) makin meningkat di negara berkembang dan menduduki peringkat 
ke-5 pada laki-laki dan ke-7 pada perempuan. Di kawasan Asia dilaporkan bahwa penyebab utamanya adalah 
hepatitis B kronik. Pilihan pengobatan untuk KHS adalah reseksi hati namun sering tidak mampu laksana 
karena penyakit tersebut sudah memasuki stadium lanjut. Karena kurangnya pilihan terapi pada KHS maka 
dipikirkan berbagai alternatif lainnya yang salah satunya adalah kemoembolisasi transarterial yang diaplikasikan 
pada pasien yang tidak dapat menjalani reseksi ataupun terapi ablasi, gagal terapi. Namun kelemahan dari 
kemoembolisasi transarterial adalah angka rekurensi KHS yang sangat tinggi. Sorafenib merupakan obat anti 
angiogenik yang diterima sebagai obat sistemik pertama pada terapi KHS. Beberapa penelitian menyebutkan 
bahwa manfaat kombinasi terapi kemoembolisasi transarterial dengan pemberian Sorafenib dapat mencegah 
rekurensi KHS. Angka keberhasilan terapi kombinasi ini mencapai angka kontrol penyakit sebesar 100% 
berdasarkan response evaluation criteria in solid tumors (RECIST) dari European Association for the Study of 
the Liver (EASL).
Kata kunci: kemoembolisasi transarterial, sorafenib, kanker hati, KHS
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INTRODUCTION
Every year hepatocellular carcinoma (HCC) or 
liver cancer is being diagnosed in more than 500,000 
people world wide, including 20,000 among them in 
USA. Incidence of liver cancer rank 5 in male and 7 
in female. Incidence of HCC increases in developing 
countries. HCC is a complication commonly found 
in chronic hepatitis patients and rarely occur before 
the age of 40. HCC associated with hepatitis C virus 
infection increases rapidly in USA with the incidence 
increasing up to threefold with survival rate below 
12%. However in Asian countries, highest HCC rate 
may be associated with chronic hepatitis B infection 
as major risk factor.1,2
Standard treatment in HCC is tumor resection and is 
considered to be potential as curative therapy. However 
15% of all resection candidates usually appear with 
comorbid, such as cirrhosis, liver function disturbance, 
presence of multiple lesions, and presence of anatomic 
disturbance in the liver which disrupt resection 
process. Liver transplantation is another alternative, 
particularly in patients with decompensated liver 
cirrhosis; however, due to limited number of donors, 
this therapy is generally less performed. Sistematically, 
chemotherapy also has low survival rate and more 
oftenly causes toxicity to other body organs.1,3
Less choice of therapy in HCC reveals several other 
alternatives, including ablation as radio frequency 
ablation (RFA), percutaneous ethanol injection (PEI), 
cryoablation, and transarterial chemoembolization 
(TACE). The liver vasculature system consists of the 
hepatic artery and the portal system with hepatic artery 
acting as the main vasculature (90-100%) for the HCC 
tissue. Based on this fact, a therapy was thought to use 
hepatic artery access to overcome tumor with minimal 
side effects for non-tumor tissue.1,3
Main therapy of HCC depends on the size of tumor, 
liver function, and general performance status of 
patients. TACE is usually used in HCC cases in patients 
who cannot undergo resection or ablation therapy, 
or has ever undergone therapy, but failed. TACE is 
considered a bridging therapy to overcome patients' 
current condition in preparation for main therapy, 
which is transplantation or liver resection. Based 
on guidelines published by American Association 
for Study of Liver Disease (AASLD) and European 
Association for the Study of the Liver (EASL), TACE 
is recommended as first line non-curative therapy in 
patients with large size or multifocal HCC who could 
not undergo surgical therapy.4
As for the disadvantages of using TACE as above, 
TACE procedure includes injecting chemotherapy directly 
to the tumor lesion and performing occlusion of hepatic 
artery which then may decrease the tumor mass. However, 
unexpected event is the occurrence of devascularization 
effect which will actually increase the expression of 
proangiogenic and growth factors.4,5 This will increase 
angiogenesis in hypoxic tumor due to TACE and explain 
the weaknesses of TACE associated with tumor recurrence 
which causes patients need to undergo TACE procedure 
for 4 to 6 times. In 2007, drug named sorafenib was found; 
this drug work as inhibitor of angiogenesis process by 
stopping the work of vascular endothelial growth factor 
(VEGF). Sorafenib has been accepted as first systemic 
treatment for advanced stage of HCC and currently has 
been used in several clinical-base study.5
TRANSARTERIAL CHEMOEMBOLIZATION 
THERAPY
Curative therapy for HCC includes liver resection 
and transplantation, but this curative option is only 
applied in the early stage. In advanced stage liver 
cancer, local or systemic therapy is needed. Though 
it is so, cancer resection still hold important role in 
curative therapy of HCC. Nevertheless, recurrence 
rate of liver canceris very high, though patient has 
undergone resection therapy. Chemoembolization is a 
technique which combine intra-arterial chemotherapy 
to induce local ischemia in the tumor. In palliative 
setting, this therapy has shown quite good result in 
decreasing disease progressivity.5,6,7
First TACE succeed to be performed was performed 
by Doyon et al in 1974, where gelatin sponge was used 
as emboli agent together with anti-cancer agent first 
initiated by Yamada et al in 1983.5,8
Principle of using TACE is based on liver 
hemorrhage concept, which consists of 2 arteries: 
hepatic artery which supplies 90% of liver needs 
and portal system which supplies the rest. Park et 
al developed atechnique utilizing hepatic artery as 
target of emboli agent because it was found that 
embolization in hepatic artery gave benefit in inducing 
tumor ischemiaand did not disrupt healthy liver tissue 
circulation, as it was still supplied from portal vein.9
 Embolization causes tumor necrosis, thus failure 
of transmembrane pump system in the tumor occurs. 
This cause more significant uptake of chemotherapy 
agent by tumor cells. Concentration of chemotherapy 
agent was found up to 40 times more compared to 
healthy liver tissue.5-8
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 Agent which is currently being used is lipiodol, 
a contras made of opium seed oil. This substance 
selectively binds neovascularization and tumor 
extravascular space. Reason of this selectivity is still 
unknown yet. Maximum dose of lipiodol is 15 mL, 
however principle of lipiodol use is 1 mL/cm tumor.5,6 
Doxorubicin is the most oftenly used chemotherapy 
agent, usually used single or in combination with 
cisplatin, mitomycin or 5-FU. Other agents which can 
be used are streptozocin, vinblastine and  gemcitabine. 
There is still no research stating the superiority of each 
agents.4,5
 Barcelona Clinic Liver Cancer, in its guidelines, 
recommends the use of TACE in intermediate stage of 
HCC (OKUDA 1-2, performance score 0 and large or 
multinoduler cancer), and in particular patients with 
advanced stage HCC (OKUDA 1-2, performance score 
1 and no extrahepatic metastasis of HCC).1,5,7
 Although there is no absolute contraindication 
of TACE, there are several conditions in which 
TACE could not be performed, which is massive 
tumor or which infiltrate upto 50% of liver tissue, 
liver insufficiency or liver failure, high bilirubin 
level (more than 5 mg/dL), A-fetoprotein level more 
than 1,000 ng/mL and high LDH level (more than 
425 IU/L), and transaminase level more than100 
IU/L. Contraindication of chemotherapy agent and 
embolization is the presence of allergy or anafilaxis 
reaction history towards the agent. Condition, in which 
occlusion has happened in portal system hemorrhage, 
is also thought to disturb the continuance of healthy 
liver tissue if TACE is still continued.1,5,7
SORAFENIB THERAPY
Hepatocarcinogenesisis multifactorial process 
where a stimulus may change the genetic system in 
hepatocytes, leads to cell proliferation and death. 
Genetic changes could be accumulated in conditions, 
such as chronic hepatitis and cirrhosis in which 
recurrent destruction and hepatocyte regeneration 
occurred in short time to create hepatocyte cells with 
defects. These defects include mutation in gene p73, 
p53, Rb, APC, DLC-1 (deleted in liver cancer), p16, 
PTEN, IGF-2, BRCA2, SOCS-1, Smad2 and Smad 4. 
Cell proliferation is marked by the presence of vascular 
endothelial growth factor (VEGF) and platelet derived 
growth factor (PDGFR) molecule secretion, inducing 
the occurrence of cell and endothelial cell proliferation 
for tumor tissue neovascularization.
Presence of hypoxic condition in tissues initiates 
binding of growth factor with receptor located in the 
cell target membrane. This causes phosphorilation of 
this receptor in continuing signal through Ras protein 
to Raf kinase which is then further relayed by MAPK 
kinase (MEK) and extracellular-signal regulated kinase 
(ERK). This activation of ERK component promotes 
angiogenesis process.4,10-12
Figure 1. Angiogenesis process which is promoted by the 
activation of extracellular-signal regulated kinase4,10-12
Therapy option for advanced stage liver cancer 
is very limited, but because of study and recognition 
of growth factors, Sorafenib or also known as BAY 
43-9006 was found, which acts by disrupting MAPK 
signal pathway by holding membrane receptors, 
especially tyrosine kinase activity and relaying signal 
from RAF. Kinase receptors mentioned above are 
receptors for VEGF, PDGF, c-KIT receptor and RET 
receptors. These kinasesreally play role in proliferation 
and endothelial cell migration which is a part of tumor 
cell angiogenesis.11-14
Anti tumor effect from sorafenib is found to 
be dose-dependent when evaluated in rat model. 
Decreased angiogenesis rate was found to be 49% in 
10 mg/kg dose and even 30 mg/kg dose managed to 
inhibit tumor growth by 100% for 21 days. In human 
clinical trials, it was found that oral dose of 400 mg 
administered every 12 hours for 4 weeks has increased 
survival rate up to 9.2 months with median decrease of 
tumor growth progressivity for 4.2 months. Phase III 
study in human has been performed, and in study of 
heart and renal protection (SHARP) from March 2005 
to April 2006, it was found that there was no difference 
in tumor progression in sorafenib group compared to 
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the placebo group. Similar study conducted in Brazil, 
a restrospective study, it was found that there were a 
lot of side effects which required lowering sorafenib 
dosage. Side effects meant above were diarrhea, 
hand-foot syndrome, itchiness.15 However it was also 
mentioned that these side effect were managable and 
in the study, 11% patients had to stop from the study 
due to serious side effects.11-14
 This phase III trial also has its own bias 
factors, such as including subjects from Asia Pacific 
region with higher occurence of advanced stage of 
liver cancer, therefore the obtained effectivity rate 
of sorafenib was lower. Therefore, to obtain better 
effectivity rate, it was thought to combine 2 therapy 
modality, which are TACE and Sorafenib which both 
has the principle of decreasing tumor size by inducing 
hypoxia; the logic in sorafenib administration in this 
concept was to prevent neovascularization for tumor 
cells after embolization and chemotherapy agent 
administration into tumor cells.11-14
COMBINATION OF TACE AND SORAFENIB 
Management criteria in liver cancer (HCC) is 
based on the classification made by Barcelona Clinic 
Liver Cancer (BCLC) which divides patients into 
5 categories: 0, A, B, C, and D based on prognosis 
variable and the available choice of therapy. Based 
on this guideline, therapy option TACE and Sorafenib 
each is located in category B and C, whereas category 
D is categorized in palliative therapy. Based on this 
guidelines, TACE is performed with the purpose of 
decreasing neoplasm mass in the liver to decrease 
the stage, so patient may undergo curative therapy, 
tumor tissue resection. Nonetheless, this is rare to be 
achieved due to the hypoxic effect after TACE which 
induce angiogenesis cascade as has been discussed 
previously. Based on this concept, it was thought to 
use combination therapy of TACE and Sorafenib to 
inhibit angiogenesis reaction with Sorafenib systemic 
therapy.7
In SHARP study by Llovet et al, it was found that 
Sorafenib, inhibitor of VEGF and Raf kinase, was 
able to increase survival of patients with advanced 
stage liver cancer. Recent study using sorafenib in 
combination with TACE has shown significant result. 
Ferrel et al used conventional TACE procedure 
followed by sorafenib treatment and showed that 
this postponed cancer progressivity significantly in 
intermediate stage of HCC associated with HCV, 
without unexpected adverse effects.6,12
Pawlik et al conducted a phase II single arm study 
in 2011, a single-center prospective design to evaluate 
safety and effectivity in sorafenib use which was 
Figure 2. Management criteria in liver cancer based on classification made by Barcelona clinic liver cancer7
Hepatocellular
Carcinoma
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combined with DEB-TACE (TACE + Doxorubicin) 
in unresectable HCC patients. This study evaluated 
safety and toxicity in patients who underwent TACE 
and Sorafenib administration in advanced stage HCC. 
Secondary final target in this study was evaluating 
tumor response toward therapy which was accessed 
using MRI with contras to measure size of target lesion. 
This result was then matched with response evaluation 
criteria in solid tumors (RECIST), and contrast uptake 
degree in magnetic resonance imaging (MRI) based 
on EASL criteria.16
Patient was given regimen for 6 weeks every 
cycle, in which in the first cycle, only sorafenib was 
administered (400 mg twice daily administered 1 
week before DEB-TACE). Sorafenib was continued 
in combination with DEB-TACE starting from the 
second week. Clinical examination was performed 
every week with laboratory examination in week 3 and 
5. Sorafenib dose reduction (400 mg daily or every 2 
days) or even treatment interruption was permitted in 
patients who experienced toxicity. However, if further 
dose reduction was needed, subjects were excluded 
from the study. DEB-TACE was given at a maximum 
dose of 100 mg doxorubicin per procedure.16
All patients qualified to participate in this study was 
given 128 cycle of therapy (Sorafenib and DEB-TACE 
– 60 cycle, and only Sorafenib – 68 cycle). Median of 
treatment duration was 71 days. In the first week of 
Sorafenib administration, 91% patients experienced 
toxicity which includes fatigue in 50%, hand-foot-skin 
reaction (HSFR) in 30%, rash in 20% and upper right 
abdominal pain in 18%. Majority toxicity in the first 
week was included in category stage 1 and 2 (92%) 
compared to category 3 and 4 (8%). Grade 3 and 4 
toxicity being found was increased of lipase enzyme 
(3%) and encephalopathy (3%). During the first 
cycle, it was obtained that 30 from total of 33 patients 
experienced grade 3 or 4 toxicity associated with 
administration of combination sorafenib and DEB-
TACE. However, during cycle 2 administration, it was 
found that only 15 patients (54%) experienced grade 
3 or 4 toxicity. This can be seen in figure 3 in which 
there is comparison of toxicity in the first week with 
sorafenib alone, combination of sorafenib and DEB-
TACE in the first cycle, also toxicity cummulative 
calculation during the study.16
Figure 3. Comparison of toxicity in the use of Sorafenib in: (A) 
A week before TACE; (B) First cycle Sorafenib and TACE; (C) 
Cummulative rate incidence of toxicity during the study16
Toxicity effect
Toxicity effect
Toxicity effect
Result of study also showed that toxicity degree 
was the same in the second cycle of treatment; this 
was proved by the incidence 15 patients from 28 
patients experienced upto grade 3 or 4 toxicity. From 
all toxicity being reported, percentages of grade 3 and 
4 toxicity incidence from first and second cycle were 
17% and 16%, respectively. Figure 4 also showed 
comparison of liver function on study initiation and 
during treatment. Patient who received sorafenib 
administration before and after DEB-TACE had lower 
bilirubin level compared to patients without sorafenib 
administration (median 0.87 mg/dL vs. median 1.5 mg/
dL). Patients with base of high bilirubin level (> 2 mg/
dL) had higher bilirubin level and lower albumin level 
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compared to patients with base of normal bilirubin 
level even after DEB-TACE (total bilirubin 5.84 vs. 
0.96 mg/dL, albumin 2.9 vs. 3.4 mg/dL).16
From effectivity point of view, after one cycle of 
sorafenib and DEB-TACE, it was found that there 
was 4% decrease in tumor size (from 6.0 cm to 5.8 
cm). Treatment response was evaluated based on 
RECIST criteria from EASL with response rate of 
58% and disease control rate of 100%.16 This study 
showed that the use of combination sorafenib and 
DEB-TACE in advanced stage HCC patients was safe 
and well-tolerated by patients. This toxicity could be 
overcome by adjusting sorafenib dose which showed 
quite good response. Result of initial study showed 
that effectivity of DEB-TACE in combination with 
sorafenib revealed good success rate based on RECIST 
criteria from EASL. Data obtained in this study was 
expected to give picture on safety and effectivity of 
Sorafenib and DEB-TACE which could be areference 
for other big studies, such as Sorafenib or placebo 
in combination with TACE (SPACE) and Eastern 
cooperative oncology group (ECOG).16
Nonetheless, a study by Kudo et al also assessed 
efficacy and safety from sorafenib administration 
towards response in TACE administration in Korean 
and Japanese individuals experiencing unresectable 
HCC. This study concluded sorafenib did not give 
significant result in extending time for progressivity 
or survival rate; however, the median exhibited that 
progressivity occurs about 2 months later compared to 
the placebo group. Many factors contributed as causes, 
such as: high number of patients upto 73% needed 
reduction of sorafenib dose and 91% experienced 
drug interruption. Thus sorafenib dose needed to be 
given was 386 mg, while for the adverse effects of 
sorafenib in combination with TACE, high result was 
obtained. Therefore, it was adviced to start sorafenib 
administration with low dose or time adjustment of 
sorafenib administration with TACE, so it would be 
well-tolerated by individuals until sinergistic effects 
occurred.14
CONCLUSION
Combination of sorafenib and DEB-TACE 
use in advanced stage HCC patients was well-
tolerated by patients. Toxicity could be overcame 
by adjusting sorafenib dose, which showed good 
response. Effectivity of DEB-TACE in combination 
with sorafenib proved high success rate based on 
RECIST criteria from EASL. Further study on proper 
administration of sorafenib dose is still needed. This 
study recommended starting sorafenib treatment with 
low dose, which is then increased gradually while 
monitoring signs of toxicity.
Figure 4. Graph of bilirubin level (A), albumin (B), AST (C), and ALT (D) during the study from the initial level until the end of 
cycle 316
PeriodPeriod
Period Period
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Currently, the most effective therapy in liver cancer 
management is TACE or Sorafenib based on its disease 
stage. Currently, combination therapy which can be 
used with TACE is Sorafenib, however, further studies 
are still needed to confirm this result. Lately, study is 
performed based on reference time to progression or 
progression free survival. However, based on AASLD 
and EASL, the best reference is time to progression 
because it is more valid and is able to picture the 
effectivity of a particular therapy holistically.
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